EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Open Access · CC BY-NC 4.0

Health‐Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study

Jan Astermark iD, Susanna Ranta, Linda Myrin-Westesson, Marianne Hoffmann, Sandrine Quere, Amparo Yovanna Castro Sanchez, Susan Robson, Tünde Czirok, Riitta Lassila iD, Pål André Holme

Haemophilia · 2025

DOI: 10.1111/hae.70121 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Haemophilia, 2025. Verfasst von Jan Astermark und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, Lund University, Malmö, Sweden. Hauptthemen laut MEDLINE: Hemophilia A, Quality of Life, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Despite factor (F)VIII prophylaxis, a perceived increased risk of bleeding for some people with severe haemophilia A (PwSHA) exists, limiting physical activity (PA) and restricting quality of life (QoL).

Aim

HemiNorth 2 (EudraCT# 2020‐003256‐32) is an interventional study evaluating the impact of switching from FVIII prophylaxis to emicizumab in PwSHA without FVIII inhibitors who have a need for improved prophylaxis in the Nordic countries.

Methods

Following completion of the HemiNorth non‐interventional study (NIS), eligible participants (aged ≥ 12–61 years) were enrolled in HemiNorth 2. The primary endpoint was health‐related QoL via the Comprehensive Assessment Tool for Challenges in Hemophilia (CATCH). Secondary endpoints included PA (International Physical Activity Questionnaire‐Short Form [IPAQ‐SF]), treatment preference (Emicizumab Preference [EmiPref] survey), joint health, model‐based annualised bleeding rates (ABRs) and adverse events.

Results

Overall, 28 physically active male PwSHA were enrolled. Most baseline CATCH domains were ≤ 25 and remained consistent; mean treatment burden considerably improved from baseline for adults (−17.8) and adolescents (+16.7). IPAQ‐SF scores were consistent throughout the study. Overall, 23 of 25 (92.0%) EmiPref respondents preferred emicizumab over FVIII prophylaxis. Model‐based ABRs for treated bleeds decreased from 5.9 (95% confidence interval [CI]: 3.8–9.1) to 1.6 (95% CI: 0.9–3.0) from the NIS to HemiNorth 2, and participants with zero treated bleeds increased from 8 (28.6%) to 16 (57.1%). No new safety signals were reported.

Conclusions

Emicizumab improved treatment burden and was preferred by most participants over FVIII prophylaxis. PA levels were consistently high, and bleeding rates improved with emicizumab versus prior FVIII prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AQuality of LifeAntibodies, BispecificAntibodies, Monoclonal, HumanizedExerciseHumansMaleAdultAdolescentMiddle AgedYoung AdultChildHemorrhage

Stichwörter der Autor:innen

emicizumabexercisefactor VIIIhaemophilia Aphysical activity

Substanzen

emicizumabAntibodies, BispecificAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Translational Medicine, Lund University, Malmö, Sweden.
  • Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
  • Astrid Lindgren's Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
  • Region Västra Götaland, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Sahlgrenska Academy, Institution For Nursing Science and Health at Gothenburg University, Gothenburg, Sweden.
  • Department of Paediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.

ORCID-Profile: Jan Astermark, Riitta Lassila

Förderung

  • F. Hoffmann-La Roche Ltd

Zitieren

APA

Astermark, J., Ranta, S., Myrin-Westesson, L., Hoffmann, M., Quere, S., Sanchez, A. Y. C., Robson, S., Czirok, T., Lassila, R., & Holme, P. A. (2025). Health‐Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study. Haemophilia. https://doi.org/10.1111/hae.70121

Vancouver

Astermark J, Ranta S, Myrin-Westesson L, Hoffmann M, Quere S, Sanchez AYC, et al. Health‐Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study. Haemophilia. 2025. doi:10.1111/hae.70121

BibTeX
@article{Astermark2025,
  author = {Astermark, Jan and Ranta, Susanna and Myrin-Westesson, Linda and Hoffmann, Marianne and Quere, Sandrine and Sanchez, Amparo Yovanna Castro and Robson, Susan and Czirok, Tünde and Lassila, Riitta and Holme, Pål André},
  title = {Health‐Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70121}
}
Kostenlos starten →